$223 Bn Cancer Therapeutic Drugs Market - Global Forecasts from 2019 to 2024 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 12, 2019--
The “Cancer Therapeutic Drugs Market - Forecasts from 2019 to 2024” report has been added to ResearchAndMarkets.com’s offering.
The cancer therapeutic drugs market is projected to grow at a CAGR of 6.87% to reach US$223.141 billion by 2024 from US$149.750 billion in 2018.
The cancer therapeutic drugs market is expected to grow at a fast pace during the forecast period due to the growing incidence of cancers worldwide. Geographically, North America is expected to hold the highest market share owing to the highest health spending of the United States among all the developed regions, in addition to having a high cancer prevalence in the country. Growing adoption of unhealthy living conditions is further emanating the market growth during the forecast period.
Furthermore, growing cancer drug spending is driving the growth of the global cancer therapeutics market during the forecast period. The growing number of clinical trials have improved the chances of new innovations for targeted cancer treatment, emanating the market growth during the forecast period and beyond. Growing health awareness among people worldwide will lead to early diagnosis, further leading to the treatment of cancer, when detected at an early stage, thus, propelling the market growth in the forecast period.
Key Topics Covered:
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5.1. By age group
4.5.2. By region
4.6. Product Pipeline
5. CANCER THERAPEUTIC DRUGS MARKET BY INDICATION
5.1. Skin Cancer
5.2. Lung Cancer
5.3. Breast Cancer
5.4. Prostate Cancer
6. CANCER THERAPEUTIC DRUGS MARKET BY PRODUCT TYPE
7. CANCER THERAPEUTIC DRUGS MARKET BY GEOGRAPHY
7.1. North America
7.2. South America
7.3.3. United Kingdom
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.5. Asia Pacific
7.5.3. South Korea
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Pfizer Inc.
9.2. Celgene Corporation
9.3. F. Hoffmann-La Roche Ltd
9.4. Bristol-Myers Squibb Company
9.5. Novartis Pharmaceuticals Corporation
9.6. Janssen Global Services, LLC
9.7. Eli Lilly and Company
9.8. Merck & Co., Inc.
9.9. Astellas Pharma Inc.
For more information about this report visit https://www.researchandmarkets.com/r/ya92qu
View source version on businesswire.com:https://www.businesswire.com/news/home/20190712005409/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 07/12/2019 12:50 PM/DISC: 07/12/2019 12:50 PM